This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Trending Today: 5 Stocks in the News
by Andrew Rocco
So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.
AMZNNegative Net Change JPMPositive Net Change MSFTNegative Net Change MRKPositive Net Change AMGNPositive Net Change ORCLNegative Net Change MRNANegative Net Change COUPPositive Net Change GOOGLPositive Net Change BOXNegative Net Change NTNXPositive Net Change RIVNNegative Net Change
airlines biotechnology biotechs cloud-computing software vaccines
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
by Zacks Equity Research
bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.
GILDPositive Net Change VRTXNegative Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Presents Positive Data on MM and FL Drugs
by Zacks Equity Research
Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.
REGNPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs
The Return of "Merger Monday"
by Andrew Rocco
Two major deals in the biotech and software industry were inked this weekend.
JPMPositive Net Change JNJPositive Net Change HZNPPositive Net Change SPLKPositive Net Change COUPPositive Net Change BOXNegative Net Change IGVNegative Net Change
biotechnology biotechs gene-therapy software
Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion
by Zacks Equity Research
Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.
SNYNegative Net Change PFEPositive Net Change AMGNPositive Net Change HZNPPositive Net Change
biotechnology pharmaceuticals
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
by Zacks Equity Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
GSKPositive Net Change GILDPositive Net Change IMGNPositive Net Change ACLXNegative Net Change
biotechnology
Busy Week Highlighted by Next Fed Rate Move
by Mark Vickery
Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.
AMGNPositive Net Change HZNPPositive Net Change COUPPositive Net Change
biotechnology biotechs finance inflation interest-rate medical software
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
by Zacks Equity Research
Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.
RHHBYNegative Net Change BMYPositive Net Change EXELNegative Net Change
biotechnology pharmaceuticals
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
by Zacks Equity Research
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
BIIBNegative Net Change GILDPositive Net Change VRTXNegative Net Change TRDANegative Net Change
biotechnology pharmaceuticals
Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere
by Sheraz Mian
Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).
BMYPositive Net Change AMXNegative Net Change MRKPositive Net Change DENegative Net Change MMCNegative Net Change BUDPositive Net Change
biotechnology industrial-products pharmaceuticals
Legacy Housing (LEGH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LEGHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Esperion (ESPR) Reports Positive Data From CLEAR Study
by Zacks Equity Research
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
BIIBNegative Net Change GILDPositive Net Change VRTXNegative Net Change ESPRPositive Net Change
biotechnology pharmaceuticals
International Game Technology (IGT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gerdau (GGB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
GGBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
by Zacks Equity Research
ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.
BIIBNegative Net Change ATAINegative Net Change
biotechnology
Bucking the Trend: 3 Stocks Showing Stellar Relative Strength this Week
by Andrew Rocco
Market pullbacks can offer a treasure trove of ideas in the form of relative strength.
AMZNNegative Net Change NFLXNegative Net Change MRNANegative Net Change TOLPositive Net Change LENPositive Net Change SMCINegative Net Change
biotechnology computers earnings home-builder
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
BIIBNegative Net Change ESALYPositive Net Change ATAINegative Net Change ARKKNegative Net Change SEELPositive Net Change CMPSNegative Net Change MNMDNegative Net Change CYBNNegative Net Change
biotechnology biotechs
After Golden Cross, Advanced Energy Industries (AEIS)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AEISNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MNKDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Microchip Technology (MCHP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MCHPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Tencent Music Entertainment Group Sponsored ADR (TME) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TMENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Diodes (DIOD) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
DIODNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EnerSys (ENS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ENSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Chegg (CHGG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CHGGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines